For research use only. Not for therapeutic Use.
Tauroursodeoxycholate-d4 Sodium (CAS: 2410279-95-5), a premium pharmaceutical research compound designed for advanced studies in liver and gastrointestinal research. As a deuterated analog of Tauroursodeoxycholate sodium, it offers enhanced stability and improved pharmacokinetic properties. Tauroursodeoxycholate-d4 Sodium is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for liver diseases and gastrointestinal disorders. Trusted by leading laboratories, Tauroursodeoxycholate-d4 Sodium is your go-to solution for cutting-edge liver and gastrointestinal research. Unlock new possibilities in liver and gastrointestinal treatment with Tauroursodeoxycholate-d4 Sodium, where innovation meets reliability.
| Catalog Number | S000144 |
| CAS Number | 2410279-95-5 |
| Molecular Formula | C26H40D4NNaO6S |
| Purity | ≥95% |
| IUPAC Name | sodium;2-[[(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-2,2,4,4-tetradeuterio-3,7-dihydroxy-10,13-dimethyl-3,5,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate |
| InChI | InChI=1S/C26H45NO6S.Na/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29;/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33);/q;+1/p-1/t16-,17+,18-,19-,20+,21+,22+,24+,25+,26-;/m1./s1/i8D2,14D2; |
| InChIKey | IYPNVUSIMGAJFC-OICBMEOSSA-M |
| SMILES | [2H]C1(C[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@H](C[C@@H]2C([C@@H]1O)([2H])[2H])O)CC[C@@H]4[C@H](C)CCC(=O)NCCS(=O)(=O)[O-])C)C)[2H].[Na+] |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92(2):307-16. [3]. Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53(3):337-345. |
